**Uitdehaag *et al.* (2018) Supplementary Figure S5**. Analysis of MEK and BRAF inhibitors approved before Nov. 2013 in a 102 cell line profiling. **A,** Waterfall plots. **B**, Volcano plots. Colors are similar to Figure 5 in the main text. IC50,averages are 174 nM for trametinib, 3.4 µM for dabrafenib and 22.3 µM for vemurafenib.

C:\Users\kooijmanf\Documents\FigS5_MEK_BRAF_v6_JJK.tiff